Template:Further points for assessing the study: Difference between revisions
No edit summary |
No edit summary |
||
| Line 38: | Line 38: | ||
{| class="wikitable" style="width:75%;" | {| class="wikitable" style="width:75%;" | ||
|- | |- | ||
! width=75% style="text-align:left;" | Correct use of parametric and non-parametric tests | ! width=75% style="text-align:left;" | Correct use of parametric and non-parametric tests {{#info: Testing for normal distribution only necessary if parametric tests are used, NI: use of parametric tests without report of normal distribution testing| note}} | ||
| style="text-align:center;" | [[Correct use of parametric and non-parametric tests::{{{Correct use of parametric and non-parametric tests|}}}]] | | style="text-align:center;" | [[Correct use of parametric and non-parametric tests::{{{Correct use of parametric and non-parametric tests|}}}]] | ||
|- | |- | ||
Revision as of 06:22, 16 September 2024
This is the "Further points for assessing the study" template.
It should be called in the following format:
{{Further points for assessing the study
|Samples sufficiently large=
|power analysis performed=
|reasons given for samples=
|Ethnicity mentioned=
|Possibility of attention effects=
|Possibility of placebo effects=
|Other reasons=
|Testing for normal distribution=
|Correct application of statistical=
|Correction for multiple testing=
|Measurement of compliance=
|Blinding reliable=
|Check whether blinding was successful=
|Consistent reporting in numbers=
|Sufficient washout period=
|Tested for carry-over=
|Were sequence effects tested=
|Comprehensive and coherent reporting=
|Were side effects systematically recorded=
|Effect sizes reported=
|Side effects taken into account in the interpretation of the results=
|mono- or multicentric=
|Ethics / CoI / Funding=
}}
Edit the page to see the template text.